LAVA Medtech Acquisition Corp. Unit
LVACU
LVACU was delisted on the 19th of April, 2023.
17 hedge funds and large institutions have $19.6M invested in LAVA Medtech Acquisition Corp. Unit in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 9 reducing their positions, and 22 closing their positions.
56% less funds holding
Funds holding: 39 → 17 (-22)
71% less capital invested
Capital invested by funds: $66.5M → $19.6M (-$46.9M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 22
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 9
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$5.04M |
| 2 |
GL
Governors Lane
New York
|
-$5.04M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$4.13M |
| 4 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$3.85M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$3.24M |
LVACU Hedge Fund Activity: Q1 2022 in Review
17 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in LAVA Medtech Acquisition Corp. Unit (LVACU) for Q1 2022, worth a combined $19.6M — down 71% from $66.5M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of LVACU and 0 opened new positions — a net loss of 22 holders — while 9 trimmed existing stakes and 0 added.
The largest seller was Shaolin Capital Management, exiting entirely with an estimated $5.04M sold.
- 17 institutional investors held LAVA Medtech Acquisition Corp. Unit (LVACU) as of Q1 2022, down from 39 in Q4 2021.
- Funds reported $19.6M of LAVA Medtech Acquisition Corp. Unit stock for Q1 2022, down 71% quarter-over-quarter.
- 0 funds opened new LAVA Medtech Acquisition Corp. Unit positions in Q1 2022 and 22 closed out, a net change of -22 holders.
- The largest LAVA Medtech Acquisition Corp. Unit seller in Q1 2022 was Shaolin Capital Management, an estimated $5.04M sold.
Based on aggregated 13F filings for Q1 2022.